They do not replace GLP-1 therapy
Thalidomide a drug, perhaps known more for its controversial 1950s history as a sedative for pregnant women with morning sickness, which was withdrawn after it was found to lead to severe skeletal birth defects was repurposed and approved by the FDA about 60 years later for use in combination with dexamethasone in patients with newly diagnosed multiple myeloma
Optimizing patient selection for tirzepatide therapy Based on the SURMOUNT-OSA population, candidates for tirzepatide therapy are those with obesity defined as BMI 30
Kristina has a strong focus on weight management, utilizing evidence-based strategies to support sustainable fat loss, improve metabolic health, and enhance overall well-being
Ogawa T, Ozawa S, Shih JH, Ryu KH, Sukotjo C, Yang JM, Nishimura I